JST-010

JST-010 is a **monoclonal antibody** developed by Just - Evotec Biologics. It is currently being evaluated in Phase 1 clinical trials for its safety, tolerability, and pharmacokinetics when administered by intramuscular injection to healthy adults. The primary goal of these studies is to assess whether a single dose of JST-010 can be safely tolerated and to determine the antibody's pharmacokinetic profile. JST-010 is under investigation for the **prevention of pneumonic plague**, a serious infectious disease. Participants in trials are monitored for adverse effects, immune responses (including development of anti-drug antibodies), and overall health status over the course of up to a year following dosing. The drug is one of the latest assets being advanced by Just - Evotec Biologics, with no marketing approval or efficacy data reported as of July 2025[1][3][7][9][10].